Discover the X Factor in Wound Care
BlastX™ is a breakthrough antimicrobial wound gel powered by Next Science’s patented, non-toxic, biofilm-disruption Xbio™ technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment.29
Others only address the tip of the iceberg.
BlastX™ goes deeper to help solve the
problem of bacterial biofilm:
Mayo Clinic Study Concludes BlastX™ Significantly Improves Clinical Outcomes Related to Wound Area Reduction and Closure when compared to SOC*
A 12-week, prospective, randomized, open-label clinical trial with 43 patients at Mayo Clinic Jacksonville, FL (22-patient treatment group using biofilm-disruption gel; 21-patient control group using a broad-spectrum antimicrobial ointment).
‣‣Wound Area Reduction:
3x greater area reduction for BlastX, 71% versus 24% for control (P < .001)
Average wound size – 11cm2; Average wound duration – 21 months; Average pt. Age – 61
‣‣Wound Closure: The wound healing environment provided by BlastX resulted in a 205%* relative increase in healing versus control (52% BlastX vs. 17% control, P<.01)
Clinical and Scientific Studies on Biofilm Disruption and BlastX™
For additional clinical and scientific studies about biofilms and BlastX’s performance, download the following publications:
Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim A. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach. Wounds. Epub 2018.
Additional Published Biofilm Education
Texas Tech Research Poster Presented at SAWC Spring 2019
Kayla Bounds1, Matthew Myntti2, Jane A. Colmer-Hamood3,4, Randall Jeter1, and Abdul Hamood4,5:
1Department of Biological Sciences, Texas Tech University, Lubbock, TX; 2Next Science, Jacksonville, FL;
Departments of 3Medical Education,4Immunology and Molecular Microbiology, and 5Surgery, Texas Tech University Health Sciences Center, Lubbock, TX
Augusta University Research Poster Presented at SAWC Spring 2019
Jose A Vazquez, Sushama Wakade, Matt Myntti, Elias Manavathu
Medical College of Georgia at Augusta University, Augusta, GA, and Next Science, Jacksonville, FL., USA
Attacking Biofilm Structure: Latest Wound Healing Data Shifts Spotlight
Jeffery A. Neizgoda, MD, FACHM, MAPWCA, CHWS
Medical Director, AZH Wound & Vascular Center
President & Chief Medical Officer, WebCME
Matthew Myntti, PhD/b>
Chief Technology Officer, Next Science
Integrating Emerging Research into Biofilm Management: Targeting the Biofilm Structure
Matthew Regulski, DPM
The Wound Institute of Ocean County, NJ
Ocean County Foot and Ankle Surgical Associates, Toms River, New Jersey
SSusie Seamans, NP
Sharp Rees-Stealy Wound Clinic, San Diego, California
Elevate Your Standard of Care with Effective Antibiofilm Technology
This peer-reviewed paper supports the need for a paradigm shift toward biofilm disruption strategies for wound healing.
‣‣Upgrade your standard of care: Follow this recommended step-down/step-up approach with the use of biofilm-disruption technology for the treatment of wounds.
Independent testing conducted at the Montana State University Center for Biofilm Engineering
BlastX™ Supersedes Current Therapy by Reducing Biofilm Bacteria 4-6 Log in Laboratory Tests24,41
In in vitro studies, BlastX was compared to multiple current topical antimicrobial therapies. 24 hours after application, measurements were taken for two different kinds of biofilm bacteria (S. aureus and P. aeruginosa).
BlastX is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial- and full-thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second degree burns, and grafted and donor sites.
BlastX is non-toxic and compatible with a broad range of advanced healing modalities that set the stage for better preparation and ongoing care of the wound bed.
MPN-WEB-003 Rev C